Skip to main content
SpringerLink
Log in

Medical Management 3: Biologicals

  • Chapter
  • First Online:
Inflammatory Bowel Disease Nursing Manual

  • 1422 Accesses

Abstract

Anti-tumour necrosis factor (anti-TNF) agents have led to major progress for IBD patients refractory to conventional treatment (corticosteroids and immunosuppressive therapy). Infliximab and adalimumab have proven their efficacy for inducing and maintaining remission in CD and UC, and infliximab is also effective for acute severe colitis and perianal fistulising Crohn’s disease. For both diseases a third anti-TNF agent has demonstrated its efficacy in a randomized controlled trial. Golimumab is available for UC patients and certolizumab pegol for CD patients, but the latter only in Switzerland and Northern America.

However, managing IBD remains challenging as prognosis and outcome vary between patients. Moreover, one-third of IBD patients seem to be primary non-responders, and an additional 40% loses effect over time (secondary nonresponders).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ben-Horin S, Chowers Y (2011) Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 33:987–995

    Article  CAS  Google Scholar 

  • Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285

    Article  CAS  Google Scholar 

  • Brandse JF, van den Brink GR, Wildenberg ME et al (2015) Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149:350–355.e2

    Article  CAS  Google Scholar 

  • Breynaert C, Ferrante M, Fidder H et al (2011) Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 106:778–785

    Article  CAS  Google Scholar 

  • Colombel JF, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65

    Article  CAS  Google Scholar 

  • Colombel JF, Rutgeerts PJ, Sandborn WJ et al (2014) Adalimumab induces deep remission in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(3):414–22.e5

    Article  CAS  Google Scholar 

  • Ferrante M, Vermeire S, Rutgeerts PJ (2014) Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 13:255–266

    Article  CAS  Google Scholar 

  • Ford AC, Sandborn WJ, Khan KJ et al (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644–659; quiz 660

    Article  CAS  Google Scholar 

  • Gibson DJ, Heetun ZS, Redmond CE et al (2015) An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 13:330–335

    Article  CAS  Google Scholar 

  • Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  CAS  Google Scholar 

  • Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the classic-I trial. Gastroenterology 130:323–332

    Article  CAS  Google Scholar 

  • Ho GT, Mowat A, Potts L et al (2009) Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 29:527–534

    Article  CAS  Google Scholar 

  • Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811

    Article  Google Scholar 

  • Jørgensen KK, Olsen IC, Goll GL et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304–2316

    Article  Google Scholar 

  • Kim YH, Ye BD, Pesegova M et al (2017) DOP061 phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. J Crohn’s Colitis 11:S62

    Article  Google Scholar 

  • Laharie D, Bourreille A, Branche J et al (2015) Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab. J Crohn’s Colitis 9:S10–S11

    Article  Google Scholar 

  • Lichtenstein GR, Feagan BG, Cohen RD et al (2012) Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol 107:1409–1422

    Article  CAS  Google Scholar 

  • Long MD, Herfarth HH, Pipkin C et al (2010) Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 8:268–274

    Article  Google Scholar 

  • Pariente B, Laharie D (2014) Review article: Why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 40:338–353

    Article  CAS  Google Scholar 

  • Peyrin-Biroulet L, LĂ©mann M (2011) Review article: Remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 33:870–879

    Article  CAS  Google Scholar 

  • Peyrin-Biroulet L, Reinisch W, Colombel J-F et al (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 63:88–95

    Article  Google Scholar 

  • Rahier JF, Magro F, Abreu C et al (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8:443–468

    Article  CAS  Google Scholar 

  • Reinisch W, Sandborn WJ, Hommes DW et al (2011) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60:780–787

    Article  CAS  Google Scholar 

  • Russo EA, Iacucci M, Lindsay JO et al (2010) Survey on the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland. Eur J Gastroenterol Hepatol 22:334–339

    Article  CAS  Google Scholar 

  • Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476

    Article  CAS  Google Scholar 

  • Sandborn W (2013) Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol 9:317–320

    Google Scholar 

  • Sandborn WJ, Rutgeerts P, Enns R et al (2007a) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838

    Article  Google Scholar 

  • Sandborn WJ, Feagan BG, Stoinov S et al (2007b) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238

    Article  CAS  Google Scholar 

  • Sandborn WJ, Van Assche G, Reinisch W et al (2012) Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142(2):257–65.e1

    Article  CAS  Google Scholar 

  • Sandborn WJ, Feagan BG, Marano C et al (2014a) Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146:85–95

    Article  CAS  Google Scholar 

  • Sandborn WJ, Feagan BG, Marano C et al (2014b) Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146(1):96–109.e1

    Article  CAS  Google Scholar 

  • Sands BE, Blank MA, Patel K et al (2004) Long-term treatment of rectovaginal fistulas in Crohn’s disease: Response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2:912–920

    Article  CAS  Google Scholar 

  • Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 357:239–250

    Article  CAS  Google Scholar 

  • Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2):CD008794. https://doi.org/10.1002/14651858.CD008794.pub2

  • Swoger JM, Loftus EV, Tremaine WJ et al (2010) Adalimumab for Crohn’s disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 16:1912–1921

    Article  Google Scholar 

  • Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al (2008) Withdrawal of Immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:1861–1868

    Article  Google Scholar 

  • Van Assche G, Vermeire S, Noman M et al (2010) Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohn’s Colitis 4:329–333

    Article  Google Scholar 

  • Vande Casteele N, Ferrante M, Van Assche G et al (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148:1320–1329.e3

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, University Hospitals Leuven, UZ Leuven, Campus Gasthuisberg, Leuven, Belgium

    Sofie Coenen, Ellen Weyts, Patricia Geens & Marc Ferrante

Authors
  1. Sofie Coenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen Weyts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia Geens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Ferrante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Ferrante .

Editor information

Editors and Affiliations

  1. DRK Kliniken Berlin Westend, Department of Gastroenterology, Berlin, Germany

    Andreas Sturm

  2. Gastroenterology Level 5, John Radcliffe Hospital, Oxford, UK

    Lydia White

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Coenen, S., Weyts, E., Geens, P., Ferrante, M. (2019). Medical Management 3: Biologicals. In: Sturm, A., White, L. (eds) Inflammatory Bowel Disease Nursing Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-75022-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75022-4_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75021-7

  • Online ISBN: 978-3-319-75022-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation